Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Iron Deficiency and Overload

Beutler, Ernest, Hoffbrand, A. Victor, Cook, James D. · 2003 · Hematology

Abstract

In the past seven years numerous genes that influence iron homeostasis have been discovered. Dr. Beutler provides a brief overview of these genes, genes that encode HFE, DMT-1, ferroportin, transferrin receptor 2, hephaestin, and hepcidin to lay the groundwork for a discussion of the various clinical forms of iron storage disease and how they differ from one another. In Section I, Dr. Beutler also discusses the types of hemochromatosis that exist as acquired and as hereditary forms. Acquired hemochromatosis occurs in patients with marrow failure, particularly when there is active ineffective erythropoiesis. Hereditary hemochromatosis is most commonly due to mutations in the HLA-linked HFE gene, and hemochromatosis clinically indistinguishable from HFE hemochromatosis is the consequence of mutations in three transferrin receptor-2 gene. A more severe, juvenile form of iron storage disease results from mutations of the gene encoding hepcidin or of a not-yet-identified gene on chromosome 1q. Autosomal dominant iron storage disease is a consequence of ferroportin mutations, and a polymorphism in the ferroportin gene appears to be involved in the African iron overload syndrome. Evidence regarding the biochemical and clinical penetrance of hemochromatosis due to mutations of the HFE gene is rapidly accumulating. These studies, emanating from several centers in Europe and the United States, all agree that the penetrance of hemochromatosis is much lower than had previously been thought. Probably only 1% of homozygotes develop clinical findings. The implications of these new findings for the management of hemochromatosis will be discussed. In Section II, Dr. Victor Hoffbrand discusses the management of iron storage disease by chelation therapy, treatment that is usually reserved for patients with secondary hemochromatosis such as occurs in the thalassemias and in patients with transfusion requirements due to myelodysplasia and other marrow failure states. Tissue iron can be estimated by determining serum ferritin levels, measuring liver iron, and by measuring cardiac iron using the MRI-T2* technique. The standard form of chelation therapy is the slow intravenous or subcutaneous infusion of desferoxamine. An orally active bidentate iron chelator, deferiprone, is now licensed in 25 countries for treatment of patients with thalassemia major. Possibly because of the ability of this compound to cross membranes, it appears to have superior cardioprotective properties. Agranulocytosis is the most serious complication of deferiprone therapy and occurs in about 1% of treated patients. Deferiprone and desferoxamine can be given together or on alternating schedules. A new orally active chelating agent ICL 670 seems promising in early clinical studies. In Section III, Dr. James Cook discusses the most common disorder of iron homeostasis, iron deficiency. He will compare some of the standard methods for identifying iron deficiency, the hemoglobin level, transferrin saturation, and mean corpuscular hemoglobin and compare these with some of the newer methods that have been introduced, specifically the percentage of hypochromic erythrocytes and reticulocyte hemoglobin content. The measurement of storage iron is achieved by measuring serum ferritin levels. The soluble transferrin receptor is a truncated form of the cellular transferrin receptor and the possible value of this measurement in the diagnosis of iron deficiency will be discussed. Until recently iron dextran was the only parental iron preparation available in the US. Sodium ferric gluconate, which has been used extensively in Europe for many years, is now available in the United States. It seems to have a distinct advantage over iron dextran in that anaphylactic reactions are much less common with the latter preparation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/asheducation-2003.1.40

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 143

  1. Beutler E, Barton JC, Felitti VJ, et al. Ferroportin (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis.2003;In press. · DOI
  2. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516–520. · DOI · Paper page
  3. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med. 2002;136:667–672. · DOI
  4. De Braekeleer M, St-Pierre C, Vigneault A, Simard H, De Medicis E. Hemochromatosis and pyruvate kinase deficiency. Report of a case and review of the literature. Blut. 1991;62:188–189.
  5. Zanella A, Berzuini A, Colombo MB, et al. Iron status in red cell pyruvate kinase deficiency: Study of Italian cases. Br J Haematol. 1993;83:485–490. · DOI
  6. Bird AR, Jacobs P, Moores P. Congenital dyserythropoietic anaemia (type II) presenting with haemosiderosis. Acta Haematol (Basel). 1987;78:33–36. · doi:10.1159/000205832
  7. Cazzola M, Barosi G, Bergamaschi G, et al. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol. 1983;54:649–654. · doi:10.1111/j.1365-2141.1983.tb02145.x
  8. Facon T, Mannessier L, Lepelley P, et al. Congenital diserythropoietic anemia type I. Report on monozygotic twins with associated hemochromatosis and short stature. Blut. 1990;61:248–250. · doi:10.1007/bf01744140
  9. Greiner TC, Burns CP, Dick FR, Henry KM, Mahmood I. Congenital dyserythropoietic anemia type II diagnosed in a 69- year-old patient with iron overload. Am J Clin Pathol. 1992;98:522–525. · doi:10.1093/ajcp/98.5.522
  10. Halpern Z, Rahmani R, Levo Y. Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type 2. Acta Haematol (Basel). 1985;74:178–180. · DOI
  11. Chiba Y, Takizawa S, Kishi K, et al. A new glucose 6-phosphate dehydrogenase (G6PD) variant (G6PD Niigata) with chronic hemolysis and liver hemochromatosis. Jpn J Int Med. 1989;78:41–47. · doi:10.2169/naika.78.41
  12. O’Mahony S, O’Brien PA, Whelton MJ. Genetic haemochromatosis and congenital spherocytosis. Lancet. 1987;1:282. · DOI
  13. Brandenberg JB, Demarmels BF, Lutz HU, Wuillemin WA. Hereditary spherocytosis and hemochromatosis. Ann Hematol. 2002;81:202–209. · doi:10.1007/s00277-002-0432-0
  14. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood. 1988;71:305–312. · DOI
  15. Deugnier Y, Jouanolle AM, Chaperon J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol. 2002;118:1170–1178. · DOI
  16. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of the 845G6A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211–218. · DOI · Paper page
  17. Waalen J, Felitti VJ, Gelbart T, Ho NJ, Beutler E. Penetrance of hemochromatosis. Blood Cells Mol Dis. 2002;29:418–432. · DOI
  18. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830–836. · DOI · Paper page
  19. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med. 1998;129:946–953. · DOI
  20. McCune CA, Al Jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet. 2002;111:538–543. · DOI
  21. MacDonald RA. Hemochromatosis and cirrhosis in different geographic areas. Am J Med Sci. 1965;249:36–46. · doi:10.1097/00000441-196501000-00006
  22. MacSween RNM, Scott AR. Hepatic cirrhosis: A clinicopathological review of 520 cases. J Clin Pathol. 1972;26: 936.
  23. Lindmark B, Eriksson S. Regional differences in the idiopathic hemochromatosis gene frequency in Sweden. Acta Med Scand. 1985;218:299–304. · DOI
  24. Adams P, Brissot P, Powell L. EASL International Consensus Conference on Haemochromatosis - Part II. Expert document. J Hepatol. 2000;33:487–496. · DOI · Paper page
  25. Beutler E, Ho N, Gelbart T. Low clinical penetrance of homozygotes for hemochromatosis detected in a health screening clinic. Blood. 2000;96:484a.
  26. Allen KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE carriers. Lancet. 2002;360:412–413. · DOI
  27. Cox T, Rochette J, Camaschella C, Walker A, Robson K. Clinical haemochromatosis in HFE carriers. Lancet. 2002;360:412. · DOI
  28. Beutler E, Felitti VJ, Koziol JA, Gelbart T. Penetrance of the 845G6A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Reply. Lancet. 2002;360:413–414. · doi:10.1016/s0140-6736(02)09584-3
  29. Beutler E. The clinical penetrance of hereditary hemochromatosis. Hepatology. 2003;37:711. · DOI
  30. Beutler E. Response to Ajioka and Kushner. Blood. 2003;101:3354–3357. · doi:10.1182/blood-2002-12-3926
  31. Piippo K, Louhijua J, Tilvis R, Kontula K. You may live to the age of more than 100 years even if you are homozygous for a haemochromatosis gene mutation. Eur J Clin Invest. 2003;33:830–831. · doi:10.1046/j.1365-2362.2003.01210.x
  32. Åsberg A, Hveem K, Kruger O, Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol. 2002;37:719–724. · DOI
  33. Phatak PD, Ryan DH, Cappuccio J, et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis. 2002;29:41–47. · DOI
  34. Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case-control study. Hum Mol Genet. 2003;12:1361–1365. · DOI
  35. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343:1529–1535. · DOI · Paper page
  36. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718–724. · DOI · Paper page
  37. Åsberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36:1108–1115. · DOI · Paper page
  38. Beutler E. Genetic irony beyond haemochromatosis: Clinical effects of HLA-H mutations. Lancet. 1997;349:296–297. · DOI
  39. Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care. 2001;24:1187–1191. · DOI
  40. Kwan T, Leber B, Ahuja S, Carter R, Gerstein HC. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clinical & Investigative Medicine. 1998;21:251–257.
  41. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268–1273. · DOI · Paper page
  42. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation - A prospective cohort study in men in eastern Finland. Circulation. 1999;100:1274–1279. · DOI · Paper page
  43. Geier D, Hebert B, Potti A. Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. Anticancer Res. 2002;22:3797–3799.
  44. Shaheen NJ, Silverman LM, Keku T, et al. Association Between Hemochromatosis (HFE) Gene Mutation Carrier Status and the Risk of Colon Cancer. JNCI. 2003;95:154–159. · DOI
  45. Bozzini C, Girelli D, Tinazzi E, et al. Biochemical and genetic markers of iron status and the risk of coronary artery disease: An angiography-based study. Clin Chem. 2002;48:622–628. · DOI
  46. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002;113:472–479. · DOI
  47. Tannapfel A, Stolzel U, Kostler E, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Archiv-An International Journal of Pathology. 2001;439:1–5. · DOI
  48. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95:1565–1571. · DOI · Paper page
  49. Beutler E, Felitti V, Gelbart T, Waalen J. Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol. 2003;120:887–893. · DOI
  50. Khoury MJ, McCabe LL, McCabe ERB. Genomic medicine - Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50–58. · DOI · Paper page
  51. MacDonald RA. Primary hemochromatosis: Inherited or adquired? Prog Hematol. 1966;5:324–353.
  52. Sheldon JH. Haemochromatosis. London: Oxford University Press; 1935.
  53. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol. 2003;30:131–136. · DOI
  54. Beutler E, Felitti V, Ho N, Gelbart T. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol (Basel). 2002;107:145–149. · DOI
  55. Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002;36:673–678. · DOI · Paper page
  56. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis. Ann Intern Med. 2003;138:627–633. · DOI · Paper page
  57. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 1996;22:187–194. · DOI · Paper page
  58. Carella M, D’Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 1997;60:828–832.
  59. Bezwoda WR, Disler PB, Lynch SR, et al. Patterns of food iron absorption in iron-deficient white and Indian subjects and in venesected haemochromatotic patients. Br J Haematol. 1976;33:425–436. · DOI
  60. Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, Leitman SF. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion. 2001;41:819–827. · DOI
  61. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33:647–651. · DOI · Paper page
  62. Brage A, Tome S, Figueruela B, Abdulkader I, Martinez J, Varo E. Hepatoma in a 40-year old male with hereditary hemochromatosis in the absence of cirrhosis. Implications of molecular diagnosis. Rev Esp Enferm Dig. 2002;94:493–499.
  63. Britto MRC, Thomas LA, Balaratnam N, Griffiths AP, Duane PD. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol. 2000;35:889–893. · DOI
  64. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256–1262. · DOI · Paper page
  65. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929–936. · DOI · Paper page
  66. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239–252. · DOI · Paper page
  67. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Clin Haematol. 2002;15:329–368.
  68. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331:574–578. · DOI · Paper page
  69. Telfer PT, Prescott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977. · DOI · Paper page
  70. Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938–948. · doi:10.1046/j.1365-2141.2003.04297.x
  71. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17–21. · DOI · Paper page
  72. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–573. · DOI · Paper page
  73. Anderson LJ, Wonke N, Prescott E, et al. Improved myocardial iron levels and ventricular function with oral deferiprone compared with subcutaneous desferrioxamine in thalassaemia. Lancet. 2002;360:516–520. · DOI · Paper page
  74. Jensen P D, Jensen FT, Christensen T, et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632–4639. · DOI · Paper page
  75. Anderson L, Holden S, Boris B, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179. · DOI · Paper page
  76. Breuer W, Ronson A, Slotki I, et al. The assessment of serum non-transferrin-bound iron in chelation therapy and iron supplementation. Blood. 2000;95:2975–2982. · DOI
  77. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr. 1997;130:86–88. · DOI
  78. Araujo A, Kosaryon M, MacDowell A, et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol. 1996;93:835–837. · doi:10.1046/j.1365-2141.1996.d01-1743.x
  79. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusions via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229–1236. · DOI · Paper page
  80. Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematol. 1996;95:26–36. · DOI · Paper page
  81. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the United Kingdom: data from the U.K. Thalassaemia Register. Lancet. 2000;355:2051–2052. · DOI · Paper page
  82. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84:113–117. · DOI · Paper page
  83. Liu DY, Liu ZD, Hider RC. Oral iron chelators—development and application. Clin Haematol. 2002;15:369–384. · doi:10.1053/beha.2002.0209
  84. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;3:553–578. · DOI
  85. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24 · DOI · Paper page
  86. Al-Refaie FN, Shephard LN, Nortey P, et al. Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403–408. · DOI
  87. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo. Blood. 1995;86:2008–2013. · DOI
  88. Pootrakul P, Pornpan S, Jongkal S, et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305–310 · DOI
  89. Kontoghiorges GJ, Aldouri MA, Sheppard L, et al. 1-2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet. 1987;i:1294–1295. · DOI · Paper page
  90. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460–466. · DOI · Paper page
  91. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329–2333. · doi:10.1182/blood.v83.8.2329.2329
  92. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918–922. · DOI · Paper page
  93. Grady RW, Berdoukas V, Rachmilewitz EA, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]. Blood. 2002;100:241a.
  94. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361–364. · DOI · Paper page
  95. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489–496.
  96. Maggio A, D’Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol Dis. 2002;28:196–208. · DOI · Paper page
  97. Cohen AR, Galanella R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108:305–312. · DOI · Paper page
  98. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. In press.
  99. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330–336. · DOI · Paper page
  100. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417–423. · DOI · Paper page
  101. Wanless A, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002;100:1566–1569. · DOI · Paper page
  102. Balveer K, Pryor K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia. 2001;55:493–497.
  103. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187–189. · DOI
  104. Galanello R, Doneddu I, Dessi E, et al. Iron chelation in thalassemia major: combined treatment with deferiprone and deferoxamine [abstract]. In: 11th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases. Catania; 2001:73.
  105. Kattamis A, Kassou C, Ladis V, et al. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia [abstract]. Blood. 2002;100:11.
  106. Breuer W, Empers MJJ, Pootrakul P, et al. Deferoxamine-chelatable iron, a component of serum non-transfusion-bound iron, used for assessing chelation therapy. Blood. 2001;97:792–798. · DOI
  107. Aydinok Y, Nisli G, Kavakli K, et al. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol. 1999;102:17–21. · doi:10.1159/000040962
  108. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741–2748. · DOI
  109. Nick HP, Acklin P, Fallen B, et al. ICL 670A: a new, potent, orally active iron chelator. In: Bergeron R, Badman D, Brittenham G, eds. Iron Chelators: New Development Strategies. Ponte Vedra, FL: Saratoga Publishers; 2000:311–331.
  110. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL 670 in iron loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602. · DOI · Paper page
  111. Piga A, Galanello R, Cappellini MD, et al. Phase II study of oral chelator ICL 670 in thalassemia patients with transfusional iron overload: safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy [abstract]. Blood. 2002;100:5.
  112. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48:1066–1076. · DOI · Paper page
  113. Brugnara C, Colella GM, Cremins J, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123:660–667.
  114. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37:93–130. · DOI · Paper page
  115. Mast AE, Binder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 2002;99:1489–1491. · DOI · Paper page
  116. Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin: a metabolite with a mission. Clin Chem. 1999;45:2060–2072. · DOI · Paper page
  117. Garrett S, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol. 1994;91:21–25. · DOI
  118. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145:657–663.
  119. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood. 1986;68:726–731. · DOI · Paper page
  120. Guyatt GH, Oxman AD, Ali M, Willan A, Mcilroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7:145–153. · DOI · Paper page
  121. Barron BA, Hoyer JD, Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol. 2001;80:166–169. · DOI
  122. Kohgo Y, Nishisato T, Kondo H, Tsushima N, Niitsu Y, Urushizaki I. Circulating transferrin receptor in human serum. Br J Haematol. 1986;64:277–281. · DOI · Paper page
  123. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329:9–22. · DOI · Paper page
  124. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood. 1990;75:1870–1876. · DOI · Paper page
  125. Yeung GS, Kjarsgaard JC, Zlotkin SH. Disparity of serum transferrin measurements among different assay methods. Eur J Clin Nutr. 1998;52:801–804. · doi:10.1038/sj.ejcn.1600650
  126. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003;101:3359–3363. · DOI · Paper page
  127. Brownlie T, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr. 2002;75:734–742. · DOI · Paper page
  128. Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Hass JD. Iron supplementation improves progressive fatigue resistance during dynamic knee extension exercise in iron-depleted, nonanemic women. Am J Clin Nutr. 2003;77:441–448. · DOI · Paper page
  129. Beutler E, Larsh SE, Gurney JM. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med. 1960;52:378–394. · DOI
  130. Guyatt GH, Patterson C, Ali M, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med. 1990;88:205–209. · DOI · Paper page
  131. Intragumtornchai T, Rojnukkarin P, Swasdikul D, Israsena S. The role of serum ferritin in the diagnosis of iron deficiency anaemia in patients with liver cirrhosis. J Intern Med. 1998;243:233–241. · DOI
  132. FergusonBJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992;119:385–590.
  133. Malope BI, MacPhail AP, Alberts M, Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol. 2001;115:84–89. · DOI
  134. Fishbane S. Intravenous iron therapy: reweighing risk and reward. Semin Dialysis. 1999;12:5–8. · doi:10.1046/j.1525-139x.1999.t01-4-00001.x
  135. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10:2029–2043. · DOI
  136. Drueke TB, Barany P, Cazzola M, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol. 1997;48:1–8.
  137. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med. 1988;111:566–570.
  138. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000;109:27–32. · DOI
  139. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464–470. · DOI · Paper page
  140. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000;109:27–32. · DOI
  141. Zanen AL, Adriaasen HJ, van Brommel EF, Psthuma R, Th de Jong GM. “Oversaturation” of transferrin after intravenous ferric gluconate (Ferrlocet®) in haemodialysis patients. Nephrol Dial Transplant. 1996;11:820–824. · DOI
  142. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem. 1999;45:898–901. · DOI
  143. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830–1839. · DOI · Paper page

Cited by

Metadata

Authors
Beutler, E., Hoffbrand, A. V., & Cook, J. D.
Venue
Hematology
Published
2003-01-01
Volume
2003
Issue
1
Pages
40-61
ISSN
  • 1520-4383 (ISSN-L)
  • 1520-4391
OpenAlex
W2122529949
Cited by
224
References
5
FWCI
8.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.